On the LLC of the LLC Lilly ICOS of Lilly ICOS, a mixing enterprise between ICOS Corporaçõ and Eli Lilly and Company, is introducing in the Cialis market in the European Union, and is taking the handle regulating approvals in North America for the treatment of sexual the organic deficiency. ICOS applies its approach integrated to the organic deficiency erectile and other urológicas clutters, psoríase, inflammatory sepsis, and illnesses. All the costs of the research and the development of ICOS-TBC had been loaded to the expenditure as incurred. More specifically, it cannot have no guarantee that this product will receive approvals regulating or will obtain the commercial success or that the ability products not daily pay-empt no chance of the market that can exist for the product.

Pafase (r) was developed for Suncos Corporaçõ, the Company& #039; tadalafil no prescription the contribution of s with Daiichi Suntory Pharma Co. ICOS Corporaçõ is a company product-lead that has the skill in therapeutics protein-based and small of the molecule. Cialis is available, tadalafil no prescription for the lapsing, in approximately 30 countries that include the 15 countries members of the European Union, Australia, New Zelândia, Russia, Brazil and Saudi Arabia. In December 2002, it was announced that Pafase (r) did not demonstrate the clinical tadalafil no prescription benefit in a study of phase 3 in the sepsis severe.

2002 prominences in November 2002, a main regulating noticeable landmark had been obtained for Cialis (TM) in Europe, when the market authorization was granted by the European Commission. ICOS is a company product-lead that Tadalafil no prescription has the skill in therapeutics protein-based and small of the molecule. (1) Aytac Ia, McKinlay JB, Krane RIO tadalafil no prescription de JANEIRO. The increase first reflects the profits carried through in relation to a decision to reduce the average maturity of our wallet of investment close to the extremity them 2003 first trimesters, dislocated partially for the impact of one lower invested counterbalances average and to lower the average taxes of interest. In 2002 ends, the company told that it finished a program of phase 1 with IC485, an active tadalafil no prescription inhibitor verbal PDE-4 considered for the treatment of the illness pulmonaa obstrutiva chronicle or the artrite rheumatoid. The reduction was due to discontinuance of the activities associates with the Pafase and the programs of the antagonist of the receiver of endothelin, dislocated partially for increased costs had become related it the progression of activities of the development for our clinical candidates of the tadalafil no prescription product. Tadalafil no prescription the total reduction reflects one lower income of the contribution of the branch offices (income) of the reimbursement of the cost, that had totalized $5,3 million in the first trimester of 2003, compared the $19,4 million in the first trimester of 2002. The 152 ED affects million esteem men and its partners worldwide. (1) up to 80 percent of cases of the ED are caused by circumstances physiological, including the illness and diabetes cardiovascular, with the 20 the psychological factors that clarify percent remaining. (ICOS-TBC) during the first trimester of 2002.